Review

ace2-ig fusion protein (Assay Genie)

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Assay Genie ace2-ig fusion protein

(A) Schematic representation of our proposed treatments. SARS-CoV-2 infects <t>ACE2</t> <t>expressing</t> cells (left panel). Binding of ACE2-Ig to SARS-CoV-2 Spike protein (middle panel) or binding of RBD-Ig to the ACE2 receptor (right panel) may prevent infection. (B) Staining of cells transfected to express ACE2 with an N-terminal Flag-tag (293T-ACE2 cells) and their parental cells that do not express a tag. This staining was performed using an anti-Flag antibody. (C) Staining of 293T-ACE2 cells with RBD-Ig. (D) Left panel: Spike protein surface expression on 293T cells co-transfected with either SARS-CoV-2 Spike envelope plasmid (293T-Spike cells) or Vesicular stomatitis virus (VSV) G envelope plasmid (293T-VSV-G cells). Right panel: Staining of 293T-Spike cells with ACE2-Ig. All histograms except from those made for 293T-Parental cells, were made from GFP positive gated cells. Figures shows one representative experiment out of 3 performed.

Ace2 Ig Fusion Protein, supplied by Assay Genie, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ace2-ig fusion protein/product/Assay Genie
Average 90 stars, based on 1 article reviews

ace2-ig fusion protein - by Bioz Stars, 2026-04

90/100 stars

Images

1) Product Images from "SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection"

Article Title: SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection

Journal: bioRxiv

doi: 10.1101/2021.04.18.440302

(A) Schematic representation of our proposed treatments. SARS-CoV-2 infects ACE2 expressing cells (left panel). Binding of ACE2-Ig to SARS-CoV-2 Spike protein (middle panel) or binding of RBD-Ig to the ACE2 receptor (right panel) may prevent infection. (B) Staining of cells transfected to express ACE2 with an N-terminal Flag-tag (293T-ACE2 cells) and their parental cells that do not express a tag. This staining was performed using an anti-Flag antibody. (C) Staining of 293T-ACE2 cells with RBD-Ig. (D) Left panel: Spike protein surface expression on 293T cells co-transfected with either SARS-CoV-2 Spike envelope plasmid (293T-Spike cells) or Vesicular stomatitis virus (VSV) G envelope plasmid (293T-VSV-G cells). Right panel: Staining of 293T-Spike cells with ACE2-Ig. All histograms except from those made for 293T-Parental cells, were made from GFP positive gated cells. Figures shows one representative experiment out of 3 performed.

Figure Legend Snippet: (A) Schematic representation of our proposed treatments. SARS-CoV-2 infects ACE2 expressing cells (left panel). Binding of ACE2-Ig to SARS-CoV-2 Spike protein (middle panel) or binding of RBD-Ig to the ACE2 receptor (right panel) may prevent infection. (B) Staining of cells transfected to express ACE2 with an N-terminal Flag-tag (293T-ACE2 cells) and their parental cells that do not express a tag. This staining was performed using an anti-Flag antibody. (C) Staining of 293T-ACE2 cells with RBD-Ig. (D) Left panel: Spike protein surface expression on 293T cells co-transfected with either SARS-CoV-2 Spike envelope plasmid (293T-Spike cells) or Vesicular stomatitis virus (VSV) G envelope plasmid (293T-VSV-G cells). Right panel: Staining of 293T-Spike cells with ACE2-Ig. All histograms except from those made for 293T-Parental cells, were made from GFP positive gated cells. Figures shows one representative experiment out of 3 performed.

Techniques Used: Expressing, Binding Assay, Infection, Staining, Transfection, FLAG-tag, Plasmid Preparation

(A) ACE2 enzymatic activity assay. Recombinant human ACE2 and ACE2-Ig were incubated with and without an ACE2 inhibitor, then MCA based peptide substrate was added and plate was immediately inserted in the fluorescent plate reader. *p<0.005, **p<0.0005, ***p<0.00005, Student’s t-test as compared to same treatment with inhibitor. (B) Staining of 293T-Spike cells with ACE2-Ig which was previously incubated for 15 minutes with or without an ACE2 inhibitor. (C-D) Plaque reduction neutralization test. Vero E6 cells were infected with SARS-CoV-2 and treated with increasing concentrations of either Control-Ig, ACE2-Ig (C) or RBD-Ig (D). % Neutralization was calculated as the percent of the decrease in plaque numbers, as compared with the background control. *P < 0.05; **P< 0.01; ***P <0.001; Student’s t-test as compared to Control-Ig. Figures shows one representative experiment out of 3 performed.

Figure Legend Snippet: (A) ACE2 enzymatic activity assay. Recombinant human ACE2 and ACE2-Ig were incubated with and without an ACE2 inhibitor, then MCA based peptide substrate was added and plate was immediately inserted in the fluorescent plate reader. *p<0.005, **p<0.0005, ***p<0.00005, Student’s t-test as compared to same treatment with inhibitor. (B) Staining of 293T-Spike cells with ACE2-Ig which was previously incubated for 15 minutes with or without an ACE2 inhibitor. (C-D) Plaque reduction neutralization test. Vero E6 cells were infected with SARS-CoV-2 and treated with increasing concentrations of either Control-Ig, ACE2-Ig (C) or RBD-Ig (D). % Neutralization was calculated as the percent of the decrease in plaque numbers, as compared with the background control. *P < 0.05; **P< 0.01; ***P <0.001; Student’s t-test as compared to Control-Ig. Figures shows one representative experiment out of 3 performed.

Techniques Used: Enzyme Activity Assay, Recombinant, Incubation, Staining, Plaque Reduction Neutralization Test, Infection, Neutralization

(A) Homozygous female K18-hACE2 transgenic mice were infected with SARS-CoV-2 (day 0) and treated with 75ug/mouse of either Control-Ig, RBD-Ig or ACE2-Ig. % of initial body weight was calculated from mice which were weighed daily. (B) Survival percentages of SARS-CoV-2 infected mice treated as described in A. *P < 0.05; Mantel-Cox test as compared to Infected + Control-Ig. Figure shows the combined results of two independent experiments.

Figure Legend Snippet: (A) Homozygous female K18-hACE2 transgenic mice were infected with SARS-CoV-2 (day 0) and treated with 75ug/mouse of either Control-Ig, RBD-Ig or ACE2-Ig. % of initial body weight was calculated from mice which were weighed daily. (B) Survival percentages of SARS-CoV-2 infected mice treated as described in A. *P < 0.05; Mantel-Cox test as compared to Infected + Control-Ig. Figure shows the combined results of two independent experiments.

Techniques Used: Transgenic Assay, Infection

(A) Anti-Spike IgG antibodies generated by mice following infection with SARS-CoV-2. Sera were taken 15 dpi from all mice groups and from naïve mice and diluted as indicated (upper right). Sera was incubated either with 293T-Spike cells (upper histograms) or with 293T-ACE2 cells (lower histograms) as a primary antibody then cells were stained with Alexa fluor 647 anti-mouse IgG secondary antibody. (B) ACE2-Ig staining of 293T-Spike cells in the presence or absence of sera from the various groups. Sera from all indicated groups were incubated with 293T-Spike cells for 1 hour at 4°C followed by staining with ACE2-Ig. All histograms were gated on GFP positive cells. Figure shows one representative experiment out of 2 performed.

Figure Legend Snippet: (A) Anti-Spike IgG antibodies generated by mice following infection with SARS-CoV-2. Sera were taken 15 dpi from all mice groups and from naïve mice and diluted as indicated (upper right). Sera was incubated either with 293T-Spike cells (upper histograms) or with 293T-ACE2 cells (lower histograms) as a primary antibody then cells were stained with Alexa fluor 647 anti-mouse IgG secondary antibody. (B) ACE2-Ig staining of 293T-Spike cells in the presence or absence of sera from the various groups. Sera from all indicated groups were incubated with 293T-Spike cells for 1 hour at 4°C followed by staining with ACE2-Ig. All histograms were gated on GFP positive cells. Figure shows one representative experiment out of 2 performed.

Techniques Used: Generated, Infection, Incubation, Staining

(A) Staining of 293T-Parental cells and 293T-ACE2 cells with the mAb anti-ACE2 01 we generated. (B) Staining of 293T-Parental cells and 293T-ACE2 cells with RBD-Ig. Cells were incubated with or without anti-ACE2 01 for 1 hour at 4°C, washed and then staining was performed. (C) Staining of infected (MOI 0.5) and uninfected VERO E6 cells with either an anti-Spike antibody to verify infection (left panel) or with our anti-ACE2 01 antibody (right panel) at 16,24,48 hours PI. (D) Staining with anti-ACE 01 of 293T-ACE2 cells which were incubated with 1 ug of either Control-Ig or RBD-Ig for 1,2,6 and 24 hours. (A-D) All histograms were gated on GFP positive cells. (E) ACE2 enzymatic activity assay. Recombinant human ACE2 and 293T-ACE2 cells lysate (10 ug) were incubated with either Control-Ig (1 ug) or RBD-Ig (0.1 ug or 1ug), then MCA based peptide substrate was added and plate was immediately read in the fluorescent plate reader. Not significant (NS), Student’s t-test as compared with Control-Ig. (F) Plaque reduction neutralization test. Vero E6 cells were infected with increasing SARS-CoV-2 titers and treated with 20 ug/well of either Control-Ig, ACE2-Ig or RBD-Ig. % Neutralization was calculated as the percent of the decrease in plaque numbers, as compared with cells treated with Control-Ig. *P < 0.01; **P< 0.005; ***P <0.00001; Student’s t-test. Figures shows one representative experiment out of 3 (A-E) or 2 (F) performed.

Figure Legend Snippet: (A) Staining of 293T-Parental cells and 293T-ACE2 cells with the mAb anti-ACE2 01 we generated. (B) Staining of 293T-Parental cells and 293T-ACE2 cells with RBD-Ig. Cells were incubated with or without anti-ACE2 01 for 1 hour at 4°C, washed and then staining was performed. (C) Staining of infected (MOI 0.5) and uninfected VERO E6 cells with either an anti-Spike antibody to verify infection (left panel) or with our anti-ACE2 01 antibody (right panel) at 16,24,48 hours PI. (D) Staining with anti-ACE 01 of 293T-ACE2 cells which were incubated with 1 ug of either Control-Ig or RBD-Ig for 1,2,6 and 24 hours. (A-D) All histograms were gated on GFP positive cells. (E) ACE2 enzymatic activity assay. Recombinant human ACE2 and 293T-ACE2 cells lysate (10 ug) were incubated with either Control-Ig (1 ug) or RBD-Ig (0.1 ug or 1ug), then MCA based peptide substrate was added and plate was immediately read in the fluorescent plate reader. Not significant (NS), Student’s t-test as compared with Control-Ig. (F) Plaque reduction neutralization test. Vero E6 cells were infected with increasing SARS-CoV-2 titers and treated with 20 ug/well of either Control-Ig, ACE2-Ig or RBD-Ig. % Neutralization was calculated as the percent of the decrease in plaque numbers, as compared with cells treated with Control-Ig. *P < 0.01; **P< 0.005; ***P <0.00001; Student’s t-test. Figures shows one representative experiment out of 3 (A-E) or 2 (F) performed.

Techniques Used: Staining, Generated, Incubation, Infection, Enzyme Activity Assay, Recombinant, Plaque Reduction Neutralization Test, Neutralization

Image Search Results

Journal: bioRxiv

Article Title: SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection

doi: 10.1101/2021.04.18.440302

Figure Lengend Snippet: (A) Schematic representation of our proposed treatments. SARS-CoV-2 infects ACE2 expressing cells (left panel). Binding of ACE2-Ig to SARS-CoV-2 Spike protein (middle panel) or binding of RBD-Ig to the ACE2 receptor (right panel) may prevent infection. (B) Staining of cells transfected to express ACE2 with an N-terminal Flag-tag (293T-ACE2 cells) and their parental cells that do not express a tag. This staining was performed using an anti-Flag antibody. (C) Staining of 293T-ACE2 cells with RBD-Ig. (D) Left panel: Spike protein surface expression on 293T cells co-transfected with either SARS-CoV-2 Spike envelope plasmid (293T-Spike cells) or Vesicular stomatitis virus (VSV) G envelope plasmid (293T-VSV-G cells). Right panel: Staining of 293T-Spike cells with ACE2-Ig. All histograms except from those made for 293T-Parental cells, were made from GFP positive gated cells. Figures shows one representative experiment out of 3 performed.

Article Snippet: The enzymatic activity of the ACE2-Ig fusion protein was evaluated using the ACE2 Activity Assay Kit (Fluorometric) (Cat#BN01071, Assay Genie) according to the manufacturer instructions.

Techniques: Expressing, Binding Assay, Infection, Staining, Transfection, FLAG-tag, Plasmid Preparation

Journal: bioRxiv

Article Title: SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection

doi: 10.1101/2021.04.18.440302

Figure Lengend Snippet: (A) ACE2 enzymatic activity assay. Recombinant human ACE2 and ACE2-Ig were incubated with and without an ACE2 inhibitor, then MCA based peptide substrate was added and plate was immediately inserted in the fluorescent plate reader. *p<0.005, **p<0.0005, ***p<0.00005, Student’s t-test as compared to same treatment with inhibitor. (B) Staining of 293T-Spike cells with ACE2-Ig which was previously incubated for 15 minutes with or without an ACE2 inhibitor. (C-D) Plaque reduction neutralization test. Vero E6 cells were infected with SARS-CoV-2 and treated with increasing concentrations of either Control-Ig, ACE2-Ig (C) or RBD-Ig (D). % Neutralization was calculated as the percent of the decrease in plaque numbers, as compared with the background control. *P < 0.05; **P< 0.01; ***P <0.001; Student’s t-test as compared to Control-Ig. Figures shows one representative experiment out of 3 performed.

Techniques: Enzyme Activity Assay, Recombinant, Incubation, Staining, Plaque Reduction Neutralization Test, Infection, Neutralization

Journal: bioRxiv

Article Title: SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection

doi: 10.1101/2021.04.18.440302

Figure Lengend Snippet: (A) Homozygous female K18-hACE2 transgenic mice were infected with SARS-CoV-2 (day 0) and treated with 75ug/mouse of either Control-Ig, RBD-Ig or ACE2-Ig. % of initial body weight was calculated from mice which were weighed daily. (B) Survival percentages of SARS-CoV-2 infected mice treated as described in A. *P < 0.05; Mantel-Cox test as compared to Infected + Control-Ig. Figure shows the combined results of two independent experiments.

Techniques: Transgenic Assay, Infection

Journal: bioRxiv

Article Title: SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection

doi: 10.1101/2021.04.18.440302

Figure Lengend Snippet: (A) Anti-Spike IgG antibodies generated by mice following infection with SARS-CoV-2. Sera were taken 15 dpi from all mice groups and from naïve mice and diluted as indicated (upper right). Sera was incubated either with 293T-Spike cells (upper histograms) or with 293T-ACE2 cells (lower histograms) as a primary antibody then cells were stained with Alexa fluor 647 anti-mouse IgG secondary antibody. (B) ACE2-Ig staining of 293T-Spike cells in the presence or absence of sera from the various groups. Sera from all indicated groups were incubated with 293T-Spike cells for 1 hour at 4°C followed by staining with ACE2-Ig. All histograms were gated on GFP positive cells. Figure shows one representative experiment out of 2 performed.

Techniques: Generated, Infection, Incubation, Staining

Journal: bioRxiv

Article Title: SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection

doi: 10.1101/2021.04.18.440302

Figure Lengend Snippet: (A) Staining of 293T-Parental cells and 293T-ACE2 cells with the mAb anti-ACE2 01 we generated. (B) Staining of 293T-Parental cells and 293T-ACE2 cells with RBD-Ig. Cells were incubated with or without anti-ACE2 01 for 1 hour at 4°C, washed and then staining was performed. (C) Staining of infected (MOI 0.5) and uninfected VERO E6 cells with either an anti-Spike antibody to verify infection (left panel) or with our anti-ACE2 01 antibody (right panel) at 16,24,48 hours PI. (D) Staining with anti-ACE 01 of 293T-ACE2 cells which were incubated with 1 ug of either Control-Ig or RBD-Ig for 1,2,6 and 24 hours. (A-D) All histograms were gated on GFP positive cells. (E) ACE2 enzymatic activity assay. Recombinant human ACE2 and 293T-ACE2 cells lysate (10 ug) were incubated with either Control-Ig (1 ug) or RBD-Ig (0.1 ug or 1ug), then MCA based peptide substrate was added and plate was immediately read in the fluorescent plate reader. Not significant (NS), Student’s t-test as compared with Control-Ig. (F) Plaque reduction neutralization test. Vero E6 cells were infected with increasing SARS-CoV-2 titers and treated with 20 ug/well of either Control-Ig, ACE2-Ig or RBD-Ig. % Neutralization was calculated as the percent of the decrease in plaque numbers, as compared with cells treated with Control-Ig. *P < 0.01; **P< 0.005; ***P <0.00001; Student’s t-test. Figures shows one representative experiment out of 3 (A-E) or 2 (F) performed.

Techniques: Staining, Generated, Incubation, Infection, Enzyme Activity Assay, Recombinant, Plaque Reduction Neutralization Test, Neutralization

Review

Structured Review

Images

1) Product Images from "SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection"

Similar Products

Image Search Results